It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Chrysin is a natural flavonoid with anti-cancer effects. Despite its beneficial effects, little information is available regarding its immunogenic cell death (ICD) properties. In this work, we hypothesized that chrysin can potentiate radiotherapy(RT)-induced immunogenicity in melanoma cell line (B16-F10). We examined the effects of chrysin alone and in combination with radiation on ICD induction in B16-F10 cells. Cell viability was assessed using an MTT assay. Cell apoptosis and calreticulin (CRT) exposure were determined using flow cytometry. Western blotting and ELISA assay were employed to examine changes in protein expression. Combination therapy exhibited a synergistic effect, with an optimum combination index of 0.66. The synergistic anti-cancer effect correlated with increased cell apoptosis in cancer cells. Compared to the untreated control, chrysin alone and in combination with RT induced higher levels of DAMPs, such as CRT, HSP70, HMGB1, and ATP. The protein expression of p-STAT3/STAT3 and PD-L1 was reduced in B16-F10 cells exposed to chrysin alone and in combination with RT. Conditioned media from B16-F10 cells exposed to mono-and combination treatments elicited IL-12 secretion in dendritic cells (DCs), inducing a Th1 response. Our findings revealed that chrysin could induce ICD and intensify the RT-induced immunogenicity.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details

1 Tabriz University of Medical Sciences, Nutrition Research Center, Tabriz, Iran (GRID:grid.412888.f) (ISNI:0000 0001 2174 8913)
2 Islamic Azad University, Science and Research Branch, Faculty of Veterinary Medicine, Tehran, Iran (GRID:grid.472472.0) (ISNI:0000 0004 1756 1816)
3 Tabriz University of Medical Sciences, Molecular Medicine Research Center, Tabriz, Iran (GRID:grid.412888.f) (ISNI:0000 0001 2174 8913); Tabriz University of Medical Sciences, Department of Pharmaceutical Biotechnology, Faculty of Pharmacy, Tabriz, Iran (GRID:grid.412888.f) (ISNI:0000 0001 2174 8913)
4 Medical Radiation Research Team, Melbourne, Australia (GRID:grid.412888.f)
5 Tabriz University of Medical Sciences, Molecular Medicine Research Center, Tabriz, Iran (GRID:grid.412888.f) (ISNI:0000 0001 2174 8913)